Акции Scribe Therapeutics упали на 4,6% на фоне разнонаправленных оценок аналитиков

Объем торгов акциями биотехнологической компании Scribe Therapeutics сократился на 68%, при этом котировки упали до $35,16. Несмотря на снижение цены, консенсус-прогноз аналитиков остается «Покупка» с целевой ценой $49.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Scribe Therapeutics Inc. (NASDAQ:SCTX – Get Free Report) shares fell 4.6% on Tuesday . The company traded as low as $35.16 and last traded at $35.53. 71,474 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 226,486 shares. The stock had previously closed at $37.25. Analyst Ratings Changes SCTX has been the subject of a number of analyst reports. Leerink Partners started coverage on shares of Scribe Therapeutics in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 target price for the company. Wells Fargo & Company initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $60.00 price objective for the company. Wall Street Zen upgraded Scribe Therapeutics to a “hold” rating in a report on Saturday, August 1st. Finally, Guggenheim initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Scribe Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $49.00. View Our Latest Research Report on Scribe Therapeutics Scribe Therapeutics Trading Down 3.5% Insider Transactions at Scribe Therapeutics Scribe Therapeutics Company Profile Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif. Recommended Stories Receive News & Ratings for Scribe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scribe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.